Skip to content
Study at a glance
AI-extracted from the abstract
Abstract
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.
Related reading
-
Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.
Diabetes Care
July 1, 2025
-
Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies
Preprints.org
June 9, 2026
-
Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi‐Dose Pens
Obesity
June 4, 2026
-
Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps.
Obesity
August 9, 2026
-
The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions
Journal of the American Association of Nurse Practitioners
May 26, 2026